This Article Full Text Full Text (PDF) All Versions of this Article: 35/11_suppl_1/2613    most recent 01.STR.0000144053.28166.a4v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Traystman, R. J. Search for Related Content PubMed PubMed Citation Articles by Traystman, R. J. Related Collections Acute coronary syndromes

(Stroke. 2004;35:2613.)
© 2004 American Heart Association, Inc.

Articles

Princeton Conference Supplement

Preface

From the Oregon Health and Science University, Portland, Ore.

Correspondence to Dr Richard J. Traystman, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mail Code L335, Portland, OR. 97239-3098. Email traystma@ohsu.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The Princeton Conference has a one-half century history as a unique, highly focused forum for the presentation and discussion of current scientific information and future directions in stroke research. The 24th Princeton Conference on Cerebrovascular Disease was held in Baltimore, Maryland, April 2 to 4, 2004, at the Baltimore Marriott Waterfront Hotel. This conference focused on the current status and future directions of stroke pathophysiology, diagnosis and treatment, with emphasis on cellular and molecular mechanisms of ischemic cell death and cell repair, and clinical aspects of imaging, risk factors, and therapeutic strategies in stroke. There were 10 major areas of presentation and discussion. The meeting began with a discussion of vascular dementia and included discussion of amyloid and epidemiology of Alzheimer disease and vascular dementias. The next discussion concerned multimodal imaging and its future in stroke. The role of sex steroids in stroke was the next area of discussion. Estrogen and progesterone were discussed as potential neuroprotection agents, and their differences as neuroprotectants in animal models was discussed in light of the recent major negative clinical trials. The ischemic penumbra, what it is, how to image it and its molecular identification was then discussed, and this was followed by an in-depth discussion of ischemic preconditioning. Cerebral ischemic preconditioning was considered from its genomic aspects and its occurrence in humans and the similarities between cerebral ischemic preconditioning and myocardial ischemic preconditioning. The conference continued forward to discuss recovery and rehabilitation in stroke, including progenitor cells, functional imaging and forced use-constraint therapy . . . [Full Text of this Article]